292 related articles for article (PubMed ID: 35998502)
21. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
22. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.
Cabel L; Proudhon C; Romano E; Girard N; Lantz O; Stern MH; Pierga JY; Bidard FC
Nat Rev Clin Oncol; 2018 Oct; 15(10):639-650. PubMed ID: 30050094
[TBL] [Abstract][Full Text] [Related]
23. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
[TBL] [Abstract][Full Text] [Related]
24. Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives.
Lu C; Zhang YC; Chen ZH; Zhou Q; Wu YL
Front Oncol; 2022; 12():836891. PubMed ID: 35359372
[TBL] [Abstract][Full Text] [Related]
25. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab.
Raja R; Kuziora M; Brohawn PZ; Higgs BW; Gupta A; Dennis PA; Ranade K
Clin Cancer Res; 2018 Dec; 24(24):6212-6222. PubMed ID: 30093454
[TBL] [Abstract][Full Text] [Related]
26. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
27. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy.
Sivapalan L; Murray JC; Canzoniero JV; Landon B; Jackson J; Scott S; Lam V; Levy BP; Sausen M; Anagnostou V
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657818
[TBL] [Abstract][Full Text] [Related]
28. Tumor Mutational Burden and
Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
[TBL] [Abstract][Full Text] [Related]
29. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
30. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
31. Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy.
Araujo DV; Wang A; Torti D; Leon A; Marsh K; McCarthy A; Berman H; Spreafico A; Hansen AR; Razak AA; Bedard PL; Wang L; Plackmann E; Chow H; Bao H; Wu X; Pugh TJ; Siu LL
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34056539
[TBL] [Abstract][Full Text] [Related]
32. Current and Future Clinical Applications of ctDNA in Immuno-Oncology.
Stadler JC; Belloum Y; Deitert B; Sementsov M; Heidrich I; Gebhardt C; Keller L; Pantel K
Cancer Res; 2022 Feb; 82(3):349-358. PubMed ID: 34815256
[TBL] [Abstract][Full Text] [Related]
33. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
34. How to use liquid biopsies to treat patients with cancer.
De Mattos-Arruda L; Siravegna G
ESMO Open; 2021 Apr; 6(2):100060. PubMed ID: 33647598
[TBL] [Abstract][Full Text] [Related]
35. Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy.
Jung SH; Lee CK; Kwon WS; Yun S; Jung M; Kim HS; Chung HC; Chung YJ; Rha SY
Yonsei Med J; 2023 Sep; 64(9):531-540. PubMed ID: 37634629
[TBL] [Abstract][Full Text] [Related]
36. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.
Del Re M; van Schaik RHN; Fogli S; Mathijssen RHJ; Cucchiara F; Capuano A; Scavone C; Jenster GW; Danesi R
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188463. PubMed ID: 33137405
[TBL] [Abstract][Full Text] [Related]
37. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.
Jang A; Lanka SM; Jaeger EB; Lieberman A; Huang M; Sartor AO; Mendiratta P; Brown JR; Garcia JA; Farmer T; Sudhaman S; Mahmood T; Pajak N; Calhoun M; Dutta P; ElNaggar A; Liu MC; Barata PC
JCO Precis Oncol; 2023 Jul; 7():e2300131. PubMed ID: 37467457
[TBL] [Abstract][Full Text] [Related]
39. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
40. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Uruga H; Mino-Kenudson M
Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
